BMNDF (Biomind Labs) YoY EBITDA Growth: -800.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BMNDF Biomind Labs Inc BMNDF
24 GF Score
Price $0.25
! 4 Warning Signs
View Full Analysis

What is Biomind Labs YoY EBITDA Growth?

Biomind Labs BMNDF 24 YoY EBITDA Growth is -800.00% as of Jun. 2026. GuruFocus rates BMNDF with a GF Score™ of 24/100. The stock has 4 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Biomind Labs's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was -800.00%.

Biomind Labs's EBITDA per Share for the three months ended in Jun. 2026 was $-0.01.

Biomind Labs YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Biomind Labs's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomind Labs YoY EBITDA Growth Chart

Biomind Labs Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
0.00 35.00 64.10 78.57 -233.33

Biomind Labs Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.00 0.00 0.00 0.00 -800.00
BMNDF
24GF Score
Biomind Labs Inc BMNDF
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biomind Labs YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Biomind Labs's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-0.01--0.003)/ | -0.003 |
=-233.33 %

Biomind Labs's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0.009--0.001)/ | -0.001 |
=-800.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -800.00% mean?
Biomind Labs (BMNDF) has a YoY EBITDA Growth of -800.00% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Biomind Labs and its competitors.
Is Biomind Labs' YoY EBITDA Growth too high?
Biomind Labs' current YoY EBITDA Growth is -800.00%. Overall, Biomind Labs has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Biomind Labs' YoY EBITDA Growth compare to VRTX and REGN?
Biomind Labs' YoY EBITDA Growth of -800.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Biomind Labs and its competitors. Biomind Labs's current YoY EBITDA Growth is -800.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomind Labs stock overvalued right now?
Biomind Labs (BMNDF) has a current YoY EBITDA Growth of -800.00%. The current YoY EBITDA Growth is -800.00%. Biomind Labs' overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Biomind Labs (BMNDF), the current YoY EBITDA Growth is -800.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biomind Labs Business Description

Other Exchanges BMND:Canada
Address 701 West Georgia Street, Suite 515, Vancouver, BC, CAN, V7Y 1C6
Biomind Labs Inc is a biotech research and development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and nanotech delivery systems for a variety of psychiatric and neurological conditions. The firm is developing pharmaceutical solutions and combined formulations of the main natural psychedelic molecules with the objective of identifying novel pharmaceutical compounds for treating a wide range of therapeutic indications.
24GF Score

Get the complete analysis for BMNDF

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price